ReviewAsia Pacific allergy2026
Mast cells: The forgotten players in type 2 inflammation - From nasal cytology to chronic rhinosinusitis with nasal polyps and beyond.
Review in Asia Pacific allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mast cells represent key regulators within type 2 inflammation and contribute significantly to the pathophysiology of chronic inflammatory airway diseases. Nasal cytology has enabled their consistent identification, highlighting how their interaction with eosinophils influences inflammatory persistence, tissue remodeling, and disease severity in chronic rhinosinusitis with nasal polyps (CRSwNP). In contrast, conventional hematoxylin-eosin histopathology does not reliably visualize mast cells, potentially limiting comprehensive cellular characterization. Through cytological assessment, distinct inflammatory endotypes have been defined, including nonallergic rhinitis with mast cells and nonallergic rhinitis with eosinophils and mast cells, which may represent stages along a continuum progressing toward CRSwNP. The Clinical-Cytological Grading integrates cellular patterns with clinical parameters, identifying eosinophil-mast cell coinfiltration as a marker associated with increased disease severity and recurrence risk. Evidence from both sinonasal and extra-nasal mucosae, including eosinophilic esophagitis, further supports the relevance of mast cells within the broader network of type 2 inflammation. As therapeutic strategies increasingly target specific inflammatory pathways, accurate cellular endotyping becomes essential for refining risk stratification and optimizing biologic therapy selection. Integrating nasal cytology with histological and molecular approaches offers a pragmatic framework for advancing precision medicine in type 2 inflammatory diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.